

Identification of Miscellaneous Peptides from the Skin Secretion of the European Edible Frog, Pelophylax kl. Esculentus

Chen, X., Wang, H., Wang, L., Zhou, M., Chen, T., & Shaw, C. (2016). Identification of Miscellaneous Peptides from the Skin Secretion of the European Edible Frog, Pelophylax kl. Esculentus. The Protein Journal, 35(4), 291-299. DOI: 10.1007/s10930-016-9672-z

Published in:

The Protein Journal

Document Version:

Peer reviewed version

Queen's University Belfast - Research Portal:

Link to publication record in Queen's University Belfast Research Portal

Publisher rights

© Springer Science+Business Media New York 2016

The final publication is available at Springer via http://link.springer.com/article/10.1007%2Fs10930-016-9672-z

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

${\bf Identification\ of\ miscellaneous\ peptides\ from\ the\ skin\ secretion\ of\ the\ European\ edible}$

frog, Pelophylax kl. Esculentus

Xiaole Chen 1,* , He Wang 2,* , Lei Wang 3 , Mei Zhou 3 , Tianbao Chen 3 , Chris Shaw 3

- 1. School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China
- 2. School of Integrative Medicine, Fujian University of Traditional Chinese Medicine, China
- Medicine Natural peptide discovery group, School of Pharmacy, Queen's University, Belfast BT9 7BL,
 Northern Ireland, UK

E-mail address: leochen5139@fjmu.edu.cn (Xiaole Chen); hwang11@qub.ac.uk (He Wang)

^{*} Corresponding author. Tel: +86(0)59122862016; Fax: +86(0)59122862016

Abstract

The chemical compounds synthesised and secreted from the dermal glands of amphibian have diverse

bioactivities that play key roles in the hosts' innate immune system and in causing diverse pharmacological

effects in predators that may ingest the defensive skin secretions. As new biotechnological methods have

developed, increasing numbers of novel peptides with novel activities have been discovered from this source of

natural compounds. In this study, a number of defensive skin secretion peptide sequences were obtained from

the European edible frog, P. kl. esculentus, using a 'shotgun' cloning technique developed previously within our

laboratory. Some of these sequences have been previously reported but had either obtained from other species or

were isolated using different methods. Two new skin peptides are described here for the first time. Esculentin-2c

and Brevinin-2Tbe belong to the Esculentin-2 and Brevinin-2 families, respectively, and both are very similar to

their respective analogues but with a few amino acid differences. Further, [Asn-3, Lys-6, Phe-13] 3-14

bombesin isolated previously from the skin of the marsh frog, Rana ridibunda, was identified here in the skin of

P. kl. esculentus. Studies such as this can provide a rapid elucidation of peptide and corresponding DNA

sequences from unstudied species of frogs and can rapidly provide a basis for related scientific studies such as

those involved in systematic or the evolution of a large diverse gene family and usage by biomedical researchers

as a source of potential novel drug leads or pharmacological agents.

Key words: Amphibian; Secretion; Mass Spectrometry; Peptide; Cloning

List of Abbreviation

P.kl. Esculentus

Pelophylax kl. Esculentus Mass spectrometry

MS RACE

Rapid Amplifiction of cDNA Ends

LCQ ESI

Liquid chromatography quadrupole Electrospray ionization

1. Introduction

Amphibian skin glands produce complex mixtures of bioactive compounds that have been used in traditional and folk medicines around the world for centuries. In modern times, it has become apparent that amphibians, whose living environments are full of various kinds of microorganisms, have developed a unique survival strategy for protecting themselves against potential pathogens. These highly-efficient host-defence compounds that are secreted from the skins of amphibians are attracting ever-increasing scientific attention, as it seems that they may be good templates for the development of new antibiotics designed to combat the emergence of pathogens that are resistant to conventional antibiotics. As many studies have shown, amphibian skin secretions not only produce potent broad-spectrum antimicrobial peptides, but also a number of peptides that have very similar structures and biological activities to mammalian neuropeptides and hormones, such as the bombesins, bradykinins and tachykinins [1-2]. In early research, hundreds or even thousands of amphibians were sacrificed to obtain enough material for biological and chemical analyses, though as modern methods and technologies have developed, this killing has become unnecessary. A good example of this advanced practice can be found in the mild electrical stimulation method that releases the secretions of the granular skin glands without damaging the host. This technique continues to play a key role in isolating and identifying the active peptides contained in skin secretions and in preservation of endangered species [1-3].

Members of the family Ranidae are widely distributed in Europe, Asia and North America, with an estimated 250 different species producing a large number of diverse antimicrobial peptides, more than 400 of which have been isolated so far [4-5]. Compared with the antimicrobial peptides isolated from other species that often contain a C-terminal amide, the peptides from ranid frog skin secretions are normally of 10-47 amino acid residues with a 6-9-membered cyclic loop region with a single disulfide bridge, called the Rana box, at the C-terminus [2, 6]. Based on the similarities of sequences between individual peptides, these can be classified into 13 peptide families comprising: brevinin-1s, brevinin-2s, esculentin-1s, esculentin-2s, japonicin-2s, nigrocin-2s, palustrin-1s, palustrin-2s, ranacyclins, ranatuerin-1s, ranatuerin-2s, and temporins. Generally, ranid frog antimicrobial peptides are cationic and adopt amphipathic α -helical structures in order to readily bind to bacterial cell membranes through which they induce cell lysis [7].

Esculentin-related peptides are regarded as the earliest characterised family and are the largest skin antimicrobial peptides, consisting of 46 amino acid residues, first isolated from the European edible frog, *P. kl. esculentus* [8-9]. After these reports, more families of peptides were described from this species, including bradykinins, brevinins and temporins. This edible frog species, *P. kl. esculentus*, which is a hybridogenetic

hybrid between Rana ridibunda and Rana lessonae, is a complex and special species for study, which not only represents a rich source for novel peptide discovery but also represents an important model for studying amphibian evolution [10].

Here, we report the structures of several skin secretion peptides identified in *P. kl. esculentus* by use of "shotgun cloning" and LC/MS/MS fragmentation sequencing. Brevinin-1E and Brevinin-1Ra were previously reported from other closely related species of ranid, though this is the first time they have been found through 'shotgun' cloning. [Asn-3, Lys-6, Phe-13] 3-14-bombesin (NLGKQWAVGHFM) was identified by molecular mass fingerprinting of reverse phase HPLC fractions of skin secretion and its structure confirmed following LC/MS. Brevinin-2Tb and Esculentin-2b were obtained in previous studies of this species, however, some primary structural modifications in precursors were found here and this may arise through natural variation between individual specimens or discrete populations. This molecular natural selection provides a good basis for the diversity in chemical structure that may eventually lead to functional development and/or optimisation.

2. Materials and methods

2.1 Preparation of P. kl. esculentus skin secretion

Pelophylax kl. esculentus (n=30) obtained from a local herpetological supplier were all adults and secretion harvesting was performed in the field after which frogs were released. Gentle transdermal electrical stimulation (5V; 3ms pulses) for 30s was employed to collect skin secretions from the frog's dorsal skin. The stimulated secretions washed by deionised water from the skin were snap-frozen in liquid nitrogen and lyophilised, which was following stored at -20° C for further analysis.

2.2"Shotgun" cloning of P. kl. esculentus skin secretion-derived cDNA

Five milligrams of lyophilised skin secretion were dissolved in 1ml of cell lysis/mRNA protection buffer supplied by Dynal Biotec, UK. By the use of magnetic oligo-dT beads as described by the manufacturer (Dynal Biotec, UK), polyadenylated mRNA was isolated and subsequently subjected to 5'- and 3'-rapid amplification of cDNA ends (RACE) procedures to obtain full-length peptide precursor nucleic acid sequence data using a Switching Mechanism At 5' end of RNA Transcript (SMART) -RACE kit (Clontech, UK) essentially. Briefly, the 3'-RACE reactions employed primers, OL-Signal(5'four pairs of CCCAAAGATGTTCACCTTGAAGAAA-3')/NUP, RA-Signal(5'-ATGTTCACCATGAAGAAATC-3')/RA-AS(5'-CTATCCCACATCAGGAGACTTTCC-3'), OL-Signal/C12-OAS(5'-GACATCTGTTGTGCATTCAGCTAA-3') and OS-1(5'-GTTCACCATGAAGAAATCCCTGTTACT-3')/NUP. These primers were designed to highly-conserved domains of the 5'-untranslated regions of previously

characterized peptide precursor cDNAs from ranid frogs. Based on a pGEM-T vector system (Promega Corporation), the gel purified 3'-RACE reactions were cloned and then sequenced by an ABI 3730 automated sequencer.

2.3 Identification and structural analysis of novel peptides

Five milligrams of lyophilised skin secretion were dissolved in 0.5 ml of 0.05/99.5 (v/v) trifluoroacetic acid (TFA)/water and centrifuged for clarification of microparticulate. A linear gradient formed from trifluoroacetic acid (TFA)/water; 0.1:99.9 (v/v), to trifluoroacetic acid (TFA)/water/acetonitrile; 0.1:19.9:80.0 (v/v/v) were pumped through a 1cm×25cm Jupiter 00G4052 semi-preparative C-5 reverse phase column (Phenomenex, UK) attached to a Cecil Adept Binary HPLC system (Adept Technology, Inc. USA) in 240 min at a flow rate of 1 ml/min for elution of collected supernatant. Samples (100 μ l) were removed from each fraction in triplicate, lyophilised and stored at -20° C prior to bioactivity assays. The fractions that exhibited specified activity were subjected to Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry (MALDI-TOF) MS analysis using a Perseptive Biosystems Voyager DE instrument (Framingham, MA, USA) in positive ion mode and α -cyano-4-hydroxycinnamic acid as matrix. Internal mass calibration of the instrument with peptide standards established the accuracy of mass determinations as $\pm 0.01\%$.

2.4 Tandem mass spectrometry sequencing

20 μl of the diluted skin secretion fraction pumped directly onto an analytical HPLC column (Phenomenex C-18; 4.6 × 150 mm) connected to an LCQ Fleet ESI ion trap mass spectrometer (Thermo Fisher, San Jose, CA, USA) in the positive detection mode. The linear elution gradient was formed from 0.1/99.9 (v/v) trifluoroacetic acid (TFA)/water to trifluoroacetic acid (TFA)/water/acetonitrile; 0.1:19.9:80.0 (v/v/v) in 135 min at a flow rate 20 μl/min. Mass analysis was performed in a positive ion mode with acquired spectra in the range of m/z 500–2000 with N50% relative intensity during HPLC-MS. Parameters for electrospray ionization ion-trap mass spectrometry (ESI/MS) were: spray voltage +4.5 kV, drying gas temperature 320 °C, drying gas flow 200 μl/min, and maximum accumulation time – for the ion trap – 350 ms. The first mass analysis was performed in full scan mode, then peptide ions with N50% relative intensity were selected for fragmentation by collision induced dissociation (CID), to generate b and y ions that were detected in a second mass analysis. The instrument was controlled by Xcalibur software (Thermo, USA) and data analysis was performed using Proteome Discover 1.0 (Thermo, USA). SequestTM algorithm was employed to compare the acquired fragment ion profiles with the theoretical fragment ions generated from a FASTA database.

3. Result

3.1 Molecular cloning of novel peptide precursor-encoding cDNA

Brevinin-1, Brevinin-2, Esculentin-1, Esculentin-2 and bombesin, these five different families of bioactive peptide precursors were repeatedly cloned from the cDNA library constructed from the skin secretion of *P. kl. esculentus* using the primers that were designed from previously characterised ranid frog peptide precursor cDNAs. The nucleotide of open-reading frames of the cloned precursor transcripts and its translated amino acid sequences are illustrated in Fig 1. The deduced single copies of mature peptide sequences located at the C-terminal regions were analysed using the Basic Local Alignment Search Tool (BLAST) program of the US National Centre for Biotechnology information (NCBI) on-line portal.

Brevinin-1Ra and Brevinin-1E were previously obtained from the skin secretion of the marsh frog, *Rana ridibundus*, by high-performance liquid chromatography/ tandem mass spectrometry (HPLC/MS/MS) analysis, though according to the disadvantages of MS/MS, Lys/Gln and Ile/Leu, were not resolved as they are too close or indeed identical in molecular masses. This is the first time these two precursor sequences have been confirmed using a molecular cloning method and their first identification in *P. kl. esculentus*. Brevinin-2Tbe, belonging to the Brevinin-2 subfamily, has a precursor that displays significantly structural similarity to Brevinin-2Tb (98%) and Brevinin-2Ei (94%). The mature peptide sequence of Esculentin-2c, which belongs to Esculentin-2 subfamily, displays 95% identify with Esculentin-2b, where there are only two amino acids differences among total 37 amino acids that are Lys13 and Met29 that take the place of Ala13 and Ile29 of Esculentin-2b. All mature peptide sequences obtained in this study are compared with the most similar peptides in the database in Fig 2. Esculentin-2c and Brevinin-2Tbe has become available in Genbank Nucleotide Sequence Database though the accession code KT437660 and KT437661.

3.2 Identification and structural analyses of [Asn-3, Lys-6, Phe-13] 3-14-bombesin in reverse phase HPLC fractions of *P. kl. esculentus* skin secretion

[Asn-3, Lys-6, Phe-13] 3-14-bombesin was identified in the reverse phase HPLC fractions based on its singly-charged and mono-isotopic molecular mass [M + H]1+ m/z of 1386.59 as determined by Matrix-Assisted Laser Desorption/ Ionization Time of Flight (MALDI-TOF) mass spectrometric analysis and confirmed by LCQ ESI MS full scan. The spectrum corresponding to the primary structure of [Asp-3, Lys-6, Phe-13] 3-14-bombesin (Fig 3) was produced by entrapment of the doubly-charged ion of this peptide by the ion trap of the LCQ Fleet mass spectrometer with further determined using MS/MS fragmentation.4. **Discussion**

In order to combat the increasing emergency of multiple drug-resistances in pathogenic bacteria all over world, scientists have been searching both chemical and natural product compound libraries for new lead compounds. The unique evolution of the amphibian host defence strategy not only provides a huge variety of bioactive peptides, but also their living environments and solutions to problems can supply clues for the development of possible therapeutics of medical or veterinary significance [11]. Amphibians are described as cold-blooded vertebrates covered by a skin that is rich in secretory glands [12-14] and it is these glands that manufacture, store and release the plethora of bioactive compounds. Members of the Ranidae ('true frogs') are such a good example that their skin secretions are constructed by a diverse range of bioactive compounds besides antimicrobial peptides. Generally, there are 10-20 unique peptides produced in one species which could have differences in sizes, sequences and spectrum of actions, etc., among frogs from different families, genera and species. Moreover, even members of the same species inhabiting different zones are able to create special peptides due to natural selection, such as Esculentin-2c that we report here. This phenomenon could explain why no two species have been found so far to produce the same antimicrobial peptides [2]. Such various peptides could be regarded as lead compounds as their potencies could be enhanced by chemical modification to promote the development of new drugs.

The European edible frog, *P. kl. esculentus*, is a hybrid originally produced between female *R.ridibunda* and male *R.lessonae*, whereas the lineages of *P. kl. esculentus* are maintained by mating females of *P. kl. esculentus* by molecular cloning technology has indicated one common cDNA-encoding precursor structure, which has a highly conserved N-terminal preproregion composed of a 22 residues long hydrophobic signal peptide, either intra- or inter-specifically, and an 16-25 residues acidic propiece that is followed by a typical prohormone processing signal Lys-Arg. Finally, a single copy of the mature peptide is encoded at the carboxyl terminus of the precursor sequence.

Compared with anti-bacterial mechanisms of conventional antibiotics that select intracellular targets and cellular processes such as DNA replication, protein and cell wall synthesis, the AMPs are able to rapidly disrupt the bacterial membranes directly with low selectivity making resistance evolution more unlikely. This fundamental mechanism of action supports AMPs as good candidates for new antibiotic drug development. Moreover, frogs from different species or subspecies produce various diverse antimicrobial peptides. Even the same species of frogs that live in different habitats or environments are capable of producing distinct repertoires of antimicrobial peptides to satisfy their special survival needs. The antimicrobial peptides modified by one or

several amino acids within their sequences could display differing sizes, net charges and hydrophobicity. Therefore, these analogues could exhibit differences in the spectrum of action and bioactivities to defend against the particular microbes that these species encounter. Esculentin-2c and Brevinin-2Tbe both have high similarity to the previously isolated antimicrobial peptides Esculentin-2b and Brevinin-2Tb, where just a few amino acid differences occur. These tiny changes inside peptide sequences, induced by either natural or artificial means, could create new or even higher potency antimicrobial peptides. For example, Brevinin-1BYa recently obtained from North American Foothill yellow-legged frogs, Rana boylii, belonging to the Brevinin-1 family, has broad-spectrum antibacterial and antifungal properties [16]. New research has discovered one portion of the residues of the full-length antimicrobial peptide sequences could also be the templates of new antibiotic development as they have potent abilities against many pathogens. Take Esculentin (1-21) for example, which is the N-terminal 1-21 region of the esculentin-1a isolated from *P. kl. esculentus*, exhibits the high antimicrobial activities against the most common mastitis-causing microbes in cattle [17,18].

Bombesin and its related homologues, which take part in the synthesis of neuropeptides and hormones and have widespread effects on the gastrointestinal tract and central nervous system' secretory functions, are widely distributed in the frog skin secretions, though its analogues obtained from *P. kl. esculentus* have been rarely reported before. [Asn-3, Lys-6, Phe-13] 3-14-bombesin, originally identified from the Marsh frog, *Rana ridibunda*, has an active core of eight amino acids at the C-terminus that is responsible for binding to receptors [19-20], and here, this peptide has been characterised in the skin secretion of *P. kl. esculentus* using an LC/MS technique. It was exciting to find another neuropeptide family, bombesin, represented in *P. kl. esculentus* skin in addition to bradykinin, that provides scientists with a better understanding of the bio-actions of the skin secretion of this species and an additional choice for neuropeptide study selection.

The skin secretions of *P. kl. esculentus* are a rich source of antimicrobial peptides that have high potency against bacteria including many pathogenic strains [16,21]. As more studies are performed on the isolation of peptides from amphibians, new peptides will be discovered and more additional bioactivities will be found that could supply great clues to improve therapeutic agents and drug development for human healthcare. Due to the development of molecular techniques, especially those that can provide comparisons of the nucleotide sequences of orthologous genes, new phylogenetic analysis of relationships between species has been made possible as an addition to the classic approach of using such aspects as the fossil record and morphological characteristics. Moreover, this improved understanding of amphibian evolutionary history should be more accurate, easier to understand and hence be more commonly accepted [22, 23].

Acknowledge

This work was supported by National Nature Science Foundation, China (Grant No. 81402842), Natural Science Foundation of Fujian Province, China (Grant No. 2015J05162), Natural Science Foundation of Fujian Province, China (Grant No. 2016J01374), Fujian Provincial outstanding talents for Education and Scientific research (Grant No. JK2014016) and The doctor startup foundation of Fujian Medical University (Grant No.2012bs002).

Conflict of Interest statement

The authors declare that they have no conflict of interest.

Ethical statement

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

- 1. Pukala TL, Bowie JH, Maselli VM, Musgrave IF, Tyler MJ (2006) Host-defence peptides from the glandular secretions of amphibians: structure and activity. Natural Product Reports 23; 3: 368-393
- 2. Vanhoye D, Bruston F, Nicolas P, Amiche M (2003) Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain. European Journal of Biochemistry 270; 9: 2068-2081
- 3. Tyler MJ, Stone DJ, Bowie JH (1992) A novel method for the release and collection of dermal, glandular secretions from the skin of frogs. Journal of Pharmacological and Toxicological Methods 28; 4: 199-200
- 4. Won HS, Kim SS, Jung SJ, Son WS, Lee B, Lee BJ (2004) Research Articles Structure-Activity Relationships of Antimicrobial Peptides from the Skin of P. kl. esculentus Inhabiting in Korea. Molecules and Cells 17; 3: 469
- 5. Simmaco M, Mignogna G, Barra D (1998) Antimicrobial peptides from amphibian skin: what do they tell us?. Biopolymers 47; 6: 435-50
- 6. Basir YJ, Conlon J M (2003) Peptidomic analysis of the skin secretions of the pickerel frog Rana palustris identifies six novel families of structurally-related peptides. Peptides 24; 3: 379-383
- 7. Conlon JM, Kolodziejek J, Nowotny N (2004) Antimicrobial peptides from ranid frogs: taxonomic and phylogenetic markers and a potential source of new therapeutic agents. Biochimica Et Biophysica Acta 1696; 1:1-14
- 8. Simmaco M, Mignogna G, Barra D, Bossa F (1994) Antimicrobial peptides from skin secretions of Rana esculenta. Molecular cloning of cDNAs encoding esculentin and brevinins and isolation of new active peptides.

 The Journal of Biological Chemistry 269; 16:11956-61
- 9. Simmaco M, Mignogna G, Barra D, Bossa F (1993) Novel antimicrobial peptides from skin secretion of the European frog Rana esculenta. FEBS Letters 324; 2: 159-61
- 10. Spolsky, C., Uzzell, T (1986) Evolutionary history of the hybridogenetic hybrid frog Rana esculenta as deduced from mtDNA analyses. Molecular Biology and Evolution 3; 1: 44-56
- 11. Clarke BT (1997) The natural history of amphibian skin secretions, their normal functioning and potential medical applications. Biological Reviews of the Cambridge Philosophical Society 72; 3: 365-79
- 12. Noble GK (1931) The biology of the Amphibia. New York
- Csordás A, Michl H (1969) Primary structure of two oligopeptides of the toxin of Bombina variegata L.
 Toxicon 7; 2: 103-8

- 14. Zasloff M (1987) Magainins, a Class of Antimicrobial Peptides from Xenopus Skin: Isolation, Characterization of Two Active Forms, and Partial cDNA Sequence of a Precursor. Proceedings of the National Academy of Sciences of the United States of America 84; 15: 5449-5453
- 15. Engeler BRHU (2001) Choosy females and indiscriminate males: mate choice in mixed populations of sexual and hybridogenetic water frogs (Rana lessonae, P. kl. esculentus)
- 16. Pal T, Abraham B, Sonnevend A, Jumaa P, Conlon JM (2006) Brevinin-1BYa: a naturally occurring peptide from frog skin with broad-spectrum antibacterial and antifungal properties. International Journal of Antimicrobial Agents 27; 6: 525-529
- 17. Islas-Rodriguez AE, Marcellini L, Barra D, Mangoni ML, Orioni B, Stella L (2009) Esculentin 1-21: A linear antimicrobial peptide from frog skin with inhibitory effect on bovine mastitis-causing bacteria. Journal of Peptide Science 15; 9: 607-614
- 18. Marcellini L, Borro M, Gentile G, Rinaldi AC, Stella L, Aimola P, Barra D, Mangoni ML (2009) Esculentin-1b(1-18) a membrane-active antimicrobial peptide that synergizes with antibiotics and modifies the expression level of a limited number of proteins in Escherichia coli. The FEBS Journal 276; 19: 5647-5664
- 19. Samgina TY, Artemenko KA, Gorshkov VA, Poljakov NB, Lebedev AT (2008) Oxidation Versus Carboxamidomethylation of S-S Bond in Ranid Frog Peptides: Pro and Contra for de Novo MALDI-MS Sequencing. Journal of the American Society for Mass Spectrometry 19; 4: 479
- 20. Samgina TY, Artemenko KA, Gorshkov VA, Ogourtsov SV, Zubarev RA, Lebedev AT (2008) De novo sequencing of peptides secreted by the skin glands of the Caucasian Green Frog Rana ridibunda. Rapid Communications in Mass Spectrometry 22; 22: 3517-3525
- 21. Kyle AA, Dahl MV (2004) Topical Therapy for Fungal Infections. American Journal of Clinical Dermatology 5; 6: 443-451
- 22. Hillis DM, Davis SK (1986) Evolution of Ribosomal DNA: Fifty Million Years of Recorded History in the Frog Genus Rana. Evolution 40; 6: 1275-1288
- 23. Conlon JM, Kolodziejek J, Nowotny N (2009) Antimicrobial peptides from the skins of North American frogs. Biochimica Et Biophysica Acta 1788; 8: 1556-63
- 24. Ali MF, Knoop FC, Vaudry H, Conlon JM (2003) Characterization of novel antimicrobial peptides from the skins of frogs of the P. kl. esculentus complex. Peptides 24; 7: 955-961

- 25. Wang Y, Knoop F, Remy-Jouet I, Delarue C, Vaudry H, Conlon J (1998) Antimicrobial Peptides of the Brevinin-2 Family Isolated from Gastric Tissue of the Frog, P. kl. esculentus. Biochemical and Biophysical Research Communications 253; 3: 600
- 26. Mangoni ML, Papo N, Mignogna G, Andreu D, Shai Y, Barra D, Simmaco M (2003) Ranacyclins, a New Family of Short Cyclic Antimicrobial Peptides: Biological Function, Mode of Action, and Parameters Involved in Target Specificity. Biochemistry 42; 47: 14023
- 27. X. Chen, H. Wang, Y. Shen, L. Wang, M. Zhou, T. Chen, C. Shaw (2016) Kunitzins: Prototypes of a new class of protease inhibitor from the skin secretions of European and Asian frogs, Biochemical and Biophysical Research Communications doi: 10.1016/j.bbrc.2016.06.062
- 28. Lebedev, A. T., Damoc, E., Makarov, A. A., Samgina, T. Y (2014) Discrimination of leucine and isoleucine in peptides sequencing with Orbitrap Fusion mass spectrometer. Analytical Chemistry 86; 14: 7017-22
- 29. Samgina, T. Y., Gorshkov, V. A., Artemenko, K. A., Vorontsov, E. A., Klykov, O. V., Ogourtsov, S. V., Zubarev, R. A., Lebedev, A. T (2012) LC-MS/MS with 2D mass mapping of skin secretions' peptides as a reliable tool for interspecies identification inside Rana esculenta complex. Peptides 34; 2: 296-302
- 30. Samgina, T. Y., Gorshkov, V. A., Vorontsov, Y. A., Artemenko, K. A., Zubarev, R. A., Lebedev, A. T (2011) Mass spectrometric study of bradykinin-related peptides (BRPs) from the skin secretion of Russian ranid frogs. Rapid Communications in Mass Spectrometry Rcm 25; 7: 933-40
- 31. Chen, X., Wang, L., Wang, H., Chen, H., Zhou, M., Chen, T., Shaw, C (2011) A fish bradykinin (Arg 0, Trp 5, Leu 8-bradykinin) from the defensive skin secretion of the European edible frog, Pelophylax kl. esculentus: Structural characterization; molecular cloning of skin kininogen cDNA and pharmacological effects on mammalian smooth muscle. Peptides 32; 1: 26-30
- 32. T. Yu. Samgina, V. A. Gorshkov, Ye. A. Vorontsov, K. A. Artemenko, S. V. Ogourtsov, R. A. Zubarev, A.
 T. Lebedev (2011) Investigation of skin secretory peptidome of Rana lessonae frog by mass spectrometry.
 Journal of Analytical Chemistry 66; 13: 1298-1306
- 33. Chen, X., Wang, H., Yang, M., Wang, L., Zhou, M., Chen, T., Shaw, C (2016) Identification and bioactivity evaluation of two novel temporins from the skin secretion of the European edible frog, Pelophylax kl. esculentus. Biochemical and Biophysical Research Communications doi:10.1016/j.bbrc.2016.05.163

Data deposition footnote

The nucleotide sequence of the Brevinin-2Tbe and Esculentin-2c precursors from the skin secretion of the European edible frog, *Pelophylax kl. esculentus*, have been deposited in the EMBL Nucleotide Sequence Database under the accession code KT437661 and KT437660.

Legends to Figures

Fig 1. Nucleotide sequence and open reading frame amino acid translation of full length prepro cDNA from the skin secretion of the European edible frog Rana esculenta encoding brevinin-1E (a), brevinin-1Ra (b), brevinin-2Ec (c), Esculentin-2c (d), brevinin-Ei (e), brevinin-2Tbe (f). The double underlined sequence is the putative signal peptide. The single underlined sequence is the sequence of the mature peptide and the stop codon is indicated by an asterisk.

Fig 2. (A) A comparison of the primary structures of the Brevinin-1 and -2 related peptides isolated from frogs of the *R.esculenta* complex with those of brevinin-1 and-2 from *R.brevipoda porsa*. (B) Comparison of the amino acid sequences of Esculentin-1 and -2 related peptides from skin secretions of *R.esculenta*. The disulphide bonds formed by the identical cysteine residues were underlined. Gaps (---) were introduced to maximise the identities. Amino acids common to all the peptides in each of the two subfamilies present in skin secretions of *R.esculenta* are in shadow.

Fig 3. (A) LCQ ESI Electrospray (LCQ) MS/MS spectrum of putative bombesin-related peptide. (B) Predicted b- and y-ion MS/MS fragment ion series (singly- and doubly- charged) of [Asn-3, Lys-6, Phe-13] 3-14-bombesin. Observed ions are indicated in black typeface.

 Table 1. Skin secretion peptides isolated from Rana esculenta

Name	Sequence	M.W.	Ref.
Brevinin-1E	FLPLLAGLAANFLPKIFCKITRKC	2676	8
Brevinin-1Ea	FLPAIFRMAAKVVPTIICSITKKC	2649	8
Brevinin-1Eb	VIPFVASVAAEMQHVYCAASRKC	2480	8
Brevinin-1Ecb	FLPLLAGLAANFFPKIFCKITRKC	2712	8
Brevinin-1Ra	VIPFVASVAAEMMQHVYCAASRRC	2640	19, 20
Brevinin-2E	GIMDTLKNLAKTAGKGALQSLLNKASCKLSGQC	3361	8
Brevinin-2Ea	GILDTLKNLAISAAKGAAQGLVNKASCKLSGQC	3242	8
Brevinin-2Eb	GILDTLKNLAKTAGKGALQGLVKMASCKLSGQC	3316	8
Brevinin-2Ec	GILLDKLKNFAKTAGKGVLQSLLNTASCKLSGQC	3519	8
Brevinin-2Ed	GILDSLKNLAKNAGQILLNKASCKLSGQC	2999	8
Brevinin-2Ef	GIMDTLKNLAKTAGKGALQSLVKMASCKLSGQC	3365	25
Brevinin-2Eg	GIMDTLKNLAKTAGKGALQSLLNHASCKLSGQC	3371	25
Brevinin-2Eh	GIMDTLKNLAKTAGKGALQSLLNHASCKLSKQC	3442	25
Brevinin-2Ei	GILDTLKNLAKTAGKGILKSLVNTASCKLSGQC	3309	25
Brevinin-2Ej	GIFLDKLKNFAKGVAQSLLNKASCKLSGQC	3181	24
Brevinin-2Tbe	GILDTLKNLAKTAGKGALQSLLNHASCKLSGQC	3354	-
CPRF-Ea	GLGSILGKILNVAGKVGKTIGKVADAVGNKE	3007	24
CPRF-Eb	GLGSFLKNAIKIAGKVGSTIGKVADAIGNKE	3055	24
CPRF-Ec	GLGSFFKNAIKIAGKVGSTIGKVADAIGNKE	3091	24
Esculentin-1	GIFSKFGRKKIKNLLISGLKNVGKEVGMDVVRTGIDIAG	4884	8
	CKIKGEC		
Esculentin-1a	GIFSKLAGKKIKNLLISGLKNVGKEVGMDVVRTGIDIA	4799	8
	GCKIKGEC		
Esculentin-1b	GIFSKLAGKKLKNLLISGLKNVGKEVGMDVVRTGIDIA	4802	8
	GCKIKGEC		
Esculentin-1c	GIFSKLAGKKIKNLLISGLKNIGKEVGMDVVRTGIDIAG	4813	8
	CKIKGEC		

Esculentin-2a	GILSLVKGVAKLAGKGLAKEGGKFGLELIACKIAKQC	3711	8
Esculentin-2b	GIFSLVKGAAKLAGKGLAKEGGKFGLELIACKIAKQC	3717	8
Esculentin-2c	GIFSLVKGAAKLLGKGLAKEGGKFGLELMACKIAKQC	3778	-
Ranacyclin E	SAPRGCWTKSYPPKPCK	1904	26
Temporin-1Ec	FLPVIAGLLSKLF	1417	9,24
Peptides A1	FLPAIAGILSQLF	1388	9,24
Peptides B9	FLPLIAGLLGKLF	1400	9,24
Temproin-1Ee	FLPVIAGVLSKLF	1402	33
Temporin-1Re	FLPGLLAGLL-NH ₂	1012	33
[Asp3, Lys6,	NLGKQWAVGHFM	1386	20, 29,
Phe13]3-14-			32
bombesin			
kunitzin-RE	AAKIILNPKFRCKAAFC	1893	20,27,28
Arg ⁰ , Trp ⁵ ,	RRPPGWSPLR	1221	29, 30,
Leu ⁸ -bradykinin			31, 32

Fig 1. (a)					
	M F T	M K K S	M L L	L F F	L G T I
1		TGAAGAAATC			
		ACTTCTTTAG			
	N L S	L F E	E E R D	A D E	E E R
51	CAACTTATCT	CTTTTTGAGG	AAGAGAGAGA	TGCCGATGAA	GAAGAAAGAA
	GTTGAATAGA	GAAAAACTCC	TTCTCTCTCT	ACGGCTACTT	CTTCTTTCTT
-	R D N P	D E S	E V E	V E K R	F L P
101	GAGACAATCC	AGATGAAAGT	GAAGTTGAAG	TGGAAAAACG	ATTTCTTCCA
	CTCTGTTAGG	TCTACTTTCA	CTTCAACTTC	ACCTTTTTGC	TAAAGAAGGT
	L L A	G L A A	N F L	P K I	F C K I
151	TTGTTGGCAG	GTCTGGCTGC	TAATTTCTTG	CCGAAAATAT	TTTGTAAAAT
	AACAACCGTC	CAGACCGACG	ATTAAAGAAC	GGCTTTTATA	AAACATTTTA
	T R K	C *			
201	AACCAGAAAA	TGTTGAAACT	TTGGAATTGG	AAATCATCTG	ATGTGGAAAA
	TTGGTCTTTT	ACAACTTTGA	AACCTTAACC	TTTAGTAGAC	TACACCTTTT
251	TCATTTAGCT	AAATACACAT	CAGATGTCTT	АТАААААТА	AAGATATTGC
-	AGTAAATCGA	TTTATGTGTA	GTCTACAGAA	TATTTTTAT	TTCTATAACG
301	ATACAGAATA	ТАААААААА	ААААААААА	AAAAAAT	
	TATGTCTTAT	ATTTTTTTT	TTTTTTTTT	TTTTTTA	
<u>(b)</u>					
	M F T	M K K S	M L L	L F F	I G T I
1		TGAAGAAATC			
		ACTTCTTTAG			
	N L S	L C E	EERA	A D E	EER
51	CAACTTATCT	CTCTGTGAGG	AAGAGAGAGC	TGCTGATGAG	GAAGAAAGAA
-	GTTGAATAGA	GAGACACTCC	TTCTCTCTCG	ACGACTACTC	CTTCTTTCTT
	R D D Q	AET	E V E	V E K R	V I P
101	GAGATGATCA	AGCAGAAACA	GAGGTTGAGG	TGGAAAAACG	AGTTATACCA
	CTCTACTAGT	TCGTCTTTGT	CTCCAACTCC	ACCTTTTTGC	TCAATATGGT
	F V A	S V A A	E M M	Q H V	Y C A A
151	TTTGTGGCAA	GTGTGGCTGC	CGAAATGATG	CAGCACGTGT	ATTGTGCAGC
-	AAACACCGTT	CACACCGACG	GCTTTACTAC	GTCGTGCACA	TAACACGTCG
	S R R	C *			
201	TTCCAGAAGA	TGTTAAATTA	AATTGGAAAT	CATCTGCTGT	GGAAAATCAT
	AAGGTCTTCT	ACAATTTAAT	TTAACCTTTA	GTAGACGACA	CCTTTTAGTA
251	TTAGCTAAAT	GCTAAATGTC	TTATAAAAAA	ATAAAGTTGT	TGCATACACT
	AATCGATTTA	CGATTTACAG	AATATTTTTT	TATTTCAACA	ACGTATGTGA
301	GTTACAAAAA	ААААААААА	ААААААААА	AAAAA	
	CAATGTTTTT	TTTTTTTTT	TTTTTTTTT	TTTTTT	


	M F T	M K K S	L L L	L F F	L G T I
1	ATGTTCACCA	TGAAGAAATC	CCTGTTACTC	CTTTTCTTTC	TTGGGACCAT
	TACAAGTGGT	ACTTCTTTAG	GGACAATGAG	GAAAAGAAAG	AACCCTGGTA
	S L S	L C E	E E R N	A D E	D D G
51	CTCCTTATCT	CTCTGTGAGG	AAGAGAGAAA	TGCTGATGAG	GATGATGGGG
	GAGGAATAGA	GAGACACTCC	TTCTCTCTTT	ACGACTACTC	CTACTACCCC
	E M T E	E V K	R G I	L L D K	L K N
101	AAATGACAGA	GGAAGTAAAA	AGAGGTATCC	TCCTGGATAA	GCTGAAGAAT
	TTTACTGTCT	CCTTCATTTT	TCTCCATAGG	AGGACCTATT	CGACTTCTTA
	F A K	T A G K	G V L	Q S L	L N T A
151	TTTGCCAAGA	CAGCAGGCAA	AGGTGTGCTC	CAGAGTCTGC	TGAATACGGC
	AAACGGTTCT	GTCGTCCGTT	TCCACACGAG	GTCTCAGACG	ACTTATGCCG
	S C K	L S G	Q C *		
201	ATCTTGTAAA	CTTTCTGGAC	AATGTTAAAA	CATGAATTGG	AAGTCATTTG
	TAGAACATTI	GAAAGACCTG	TTACAATTTT	GTACTTAACC	TTCAGTAAAC
251	ATGCAGAATA	TCATTTAGCT	AAATGCTAAA	TGTCTGATAA	ААААТААААА
	TACGTCTTAT	AGTAAATCGA	TTTACGATTT	ACAGACTATT	TTTTATTTTT
301	GATCACACAA	ААААААААА	ААААААААА	ААААААА	
	CTAGTGTGTT	TTTTTTTTT	TTTTTTTTT	TTTTTTTT	
4.45					
<u>(d)</u>					
<u>(d)</u>	м	K K S	LLLL	F F I	G T I
(d) 1		AAGAAATCCC	TGTTACTCCT	F F I TTTCTTTATT AAAGAAATAA	
	GTTCACCATG	AAGAAATCCC TTCTTTAGGG	TGTTACTCCT	TTTCTTTATT	GGGACCATCT
	GTTCACCATG CAAGTGGTAC S L S I	AAGAAATCCC TTCTTTAGGG C Q E	TGTTACTCCT ACAATGAGGA E R G	TTTCTTTATT AAAGAAATAA	GGGACCATCT CCCTGGTAGA E E G
1	GTTCACCATG CAAGTGGTAC S L S L CCTTATCTCT	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG	TTTCTTTATT AAAGAAATAA A D G E	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG
1	GTTCACCATG CAAGTGGTAC S L S L CCTTATCTCT	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG
1	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG TCTCCTTCCC A A K L
1	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G	GGGACCATCT CCCTGGTAGA E E G AGAGGGAAGGG TCTCCTTCCC A A K L CAGCCAAGCT
1	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG	GGGACCATCT CCCTGGTAGA E E G AGAGGGAAGGG TCTCCTTCCC A A K L CAGCCAAGCT
1	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAAGGTG CAGTTTCCAC	GGGACCATCT
51	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGGCCA	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGGG	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG CAGTTTCCAC	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG TCTCCTTCCC A A K L CAGCCAAGCT GTCGGTTCGA L E L CTGGAGCTTA
51	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGGCCA CCAAACCGGT	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGGG	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG CAGTTTCCAC K F G CAAGTTTGGG	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG TCTCCTTCCC A A K L CAGCCAAGCT GTCGGTTCGA L E L CTGGAGCTTA
51	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA TGACCCGTTT M A C K	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGGCCA CCAAACCGGT	TGTTACTCCT ACAATGAGGA E R G GAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGGG TCCTTCCCCC	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG CAGTTTCCAC K F G CAAGTTTGGG	$\begin{array}{c c} GGGACCATCT\\ CCCTGGTAGA\\ \hline E & E & G\\ \\ AGAGGGAGGG\\ \hline TCTCCTTCCC\\ \hline A & A & K & L\\ \\ CAGCCAAGCT\\ \hline L & E & L\\ \\ CTGGAGCTA\\ \hline GACCTCGAAT\\ \\ GACCTCGAAT\\ \\ \end{array}$
1 51 151	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA TGACCCGTTT M A C K	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGGCCA CCAAACCGGT I A K AATTGCAAAA	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGGG TCCTTCCCCC Q C * CAATGTTAAA	TTTCTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG CAGTTTCCAC K F G CAAGTTTGGG GTTCAAACCC	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG TCTCCTTCCC A A K L CAGCCAAGCT GTCGGTTCGA CTGGAGCTTA GACCTCGAAT
1 51 151	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA TGACCCGTTT M A C K TGGCTTGTAAA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGCCA CCAAACCGGT I A K AATTGCAAAA	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGGG TCCTTCCCCC Q C * CAATGTTAAA GTTACAATTT	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG CAGTTTCCAC K F G CAAGTTTGGG GTTCAAACCC TCTTCAATTG	GGGACCATCT CCCTGGTAGA E E G AGAGGAAGGG TCTCCTTCCC A A K L CAGCCAAGCT GTCGGTTCGA L E L CTGGAGCTTA GACCTCGAAT GAGGTCATCT CTCCAGTAGA
1 51 101 151	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA TGACCCGTTT M A C K TGGCTTGTAAA	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGGCCA CCAAACCGGT I A K AATTGCAAAA TTAACGTTTT ATCATTAGC	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGG TCCTTCCCCC Q C * CAATGTTAAA GTTACAATTT AAAATGCTAA	TTTCTTTATT AAAGAAATAA A D G E CCGATGGAGA GGCTACCTCT V K G GTCAAAGGTG CAGTTTCCAC K F G CAAGTTTGGG GTTCAAACCC GTTCAATTGAATTGAAACCC GTTCTCAATTGAATTGAAAACCC AGAAGTTAACCAAAACCCC	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
1 51 101 151	GTTCACCATG CAAGTGGTAC S L S I CCTTATCTCT GGAATAGAGA E E M GAAGAAATGA CTTCTTTACT L G K ACTGGGCAAA TGACCCGTTT M A C K TGGCTTGTAA ACCGAACATT GATGTGGAAT	AAGAAATCCC TTCTTTAGGG C Q E CTGTCAGGAA GACAGTCCTT K R G I AAAGAGGTAT TTTCTCCATA G L A GGTTTGGCCA CCAAACCGGT I A K AATTGCAAAA TTAACGTTTT ATCATTTAGC	TGTTACTCCT ACAATGAGGA E R G GAGAGAGGCG CTCTCTCCGC F S L TTTCTCGCTA AAAGAGCGAT K E G G AGGAAGGGG TCCTTCCCCC Q C * CAATGTTAAA GTTACAATTT AAAATGCTAA	TTTCTTATT ANAGANATAN A D G E CCGATGGAGA GGCTACCTCT V K G GTCANAGGTG CAGTTTCCAC K F G CAAGTTTGGG GTTCANACCC TCTTCANTG AGANGTTAAC TTGTCTANTA	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

	H F I			T T T T T T
1	ATGTTCACCT	TGAAGAAATC	CCTGTTACTC	TTTTTCTTTC TTGGGACCAT
	TACAAGTGGA	ACTTCTTTAG	GGACAATGAG	AAAAAGAAAG AACCCTGGTA
	S L S	L C Q	E E R N	A D E D D G
51	CTCCTTATCT	CTCTGTCAGG	AAGAGAGAAA	TGCTGATGAG GACGATGGGG
	GAGGAATAGA	GAGACAGTCC	TTCTCTCTTT	ACGACTACTC CTGCTACCCC
	E M T E	E E K	R G I	L D T L K N L
101	AAATGACAGA	GGAAGAAAA	AGAGGTATCC	TGGATACGCT GAAGAATTTA
	TTTACTGTCT	CCTTCTTTTT	TCTCCATAGG	ACCTATGCGA CTTCTTAAAT
	A K T	A G K G	I L K	S L V N T A S
151	GCCAAGACAG	CAGGCAAAGG	TATACTGAAG	AGTCTGGTGA ATACGGCATC
	CGGTTCTGTC	GTCCGTTTCC	ATATGACTTC	TCAGACCACT TATGCCGTAG
	C K L	S G Q	C *	
201	TTGTAAACTT	TCTGGACAAT	GCTAAAACAT	GAATTGGAAG TCATTTGATG
	AACATTTGAA	AGACCTGTTA	CGATTTTGTA	CTTAACCTTC AGTAAACTAC
251	CAGCATATCA	TTTAGCTAAA	TACTAAATGT	CTGATAAAAA ATAAAAATAT
	GTCGTATAGT	AAATCGATTT	ATGATTTACA	GACTATTTTT TATTTTTATA
301	CACATGAAAA	АААААААА	АААААААА	AAAA
	GTGTACTTTT	TTTTTTTTT	TTTTTTTTT	TTTT
(f)				
	M F T	L K K S	L L L	F F F L G T I
1				F F F L G T I
1	ATGTTCACCT	TGAAGAAATC	CCTGTTACTC	
1	ATGTTCACCT	TGAAGAAATC	CCTGTTACTC	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA
51	ATGTTCACCT TACAAGTGGA S L S	TGAAGAAATC ACTTCTTTAG L C Q	CCTGTTACTC GGACAATGAG E E R N	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA
	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT	TGAAGAAATC ACTTCTTTAG L C Q CTCTGTCAGG	CCTGTTACTC GGACAATGAG E E R N AAGAGAGAAA	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G
	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT	TGAAGAAATC ACTTCTTTAG L C Q CTCTGTCAGG	CCTGTTACTC GGACAATGAG E E R N AAGAGAGAAA	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG
	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E	TGAAGAAATC ACTTCTTTAG L C Q CTCTGTCAGG GAGACAGTCC E E K	CCTGTTACTC GGACAATGAG E E R N AAGAGAGAAA TTCTCTCTTT R G I	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC
51	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA	$ \begin{aligned} & \text{TGAAGAAATC} \\ & \text{ACTTCTTTAG} \\ & \text{L} & \text{C} & \text{Q} \\ & \text{CTCTGTCAGG} \\ & \text{GAGACAGTCC} \\ & \text{E} & \text{K} \\ & \text{GGAAGAAAAA} \end{aligned} $	$\begin{array}{c c} \textbf{CCTGTTACTC} \\ \textbf{GGACAATGAG} \\ \textbf{E} & \textbf{E} & \textbf{R} & \textbf{N} \\ \textbf{AAGAGAGAAA} \\ \textbf{TTCTCTCTTT} \\ \textbf{R} & \textbf{G} & \textbf{I} \\ \textbf{AGAGGTATCC} \\ \end{array}$	TTTTTCTTTC TTGGGACCAT AAAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L D N L
51	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT	$ \begin{aligned} & \text{TGAAGAAATC} \\ & \text{ACTTCTTTAG} \\ & \text{L} & \text{C} & \text{Q} \\ & \text{CTCTGTCAGG} \\ & \text{GAGACAGTCC} \\ & \text{E} & \text{K} \\ & \text{GGAAGAAAAA} \end{aligned} $	$\begin{array}{c c} \textbf{CCTGTTACTC} \\ \textbf{GGACAATGAG} \\ \textbf{E} & \textbf{E} & \textbf{R} & \textbf{N} \\ \textbf{AAGAGAGAAA} \\ \textbf{TTCTCTCTTT} \\ \textbf{R} & \textbf{G} & \textbf{I} \\ \textbf{AGAGGTATCC} \\ \end{array}$	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L L K N L TGGATACGCT GAAGAATTTA GAAGAATTTA ACGACTTACCCC ACGACTTACCCCC ACGACTTACCCC
51	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T	TGAAGALATC ACTTCTTTAG L C CGAGACAAAA CCTTCTTTT A G CCTTCTTTTT A G	$\begin{array}{c c} CCTGTTACTC\\ GGACATTACTC\\ E & E & R & N\\ AAGAGATCTCTCTCTTT\\ R & G & I\\ AGAGGGTATCC\\ TCTCCCTTAGG\\ A & L & Q\\ \end{array}$	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT
101	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG	TGAAGAAATC ACTTCTTTAG L C Q CTCTGTCAGG GAGACAGTCC E E K GGAAGAAAAA CCTTCTTTTT A G K G CAGGCAAAGG	$\begin{array}{c c} CCTGTTACTC\\ GGACATTACTC\\ E & E & R & N\\ AAGAGAGAAA\\ TTCTCTCTTT\\ R & G & I\\ AGAGGTATCC\\ TCTCCATAGG\\ A & L & Q\\ TGCGCTCCAG\\ \end{array}$	TTTTTCTTTC TTGGGACCAT AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
101	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG	TGAAGAAATC ACTTCTTTAG L C Q CTCTGTCAGG GAGACAGTCC E E K GGAAGAAAAA CCTTCTTTTT A G K G CAGGCAAAGG	$\begin{array}{c c} CCTGTTACTC\\ GGACATTACTC\\ E & E & R & N\\ AAGAGAGAAA\\ TTCTCTCTTT\\ R & G & I\\ AGAGGTATCC\\ TCTCCATAGG\\ A & L & Q\\ TGCGCTCCAG\\ \end{array}$	TTTTTCTTTC TTGGGACCAT AAAAAAGAAG AACCTGGTA A D E D D G TGCTGATGAG GACGATGCGG ACGACTACTC CTGCTACCCC CC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S S L L N H A S AGTCTGCTGA ATCATGCATC ATCATGCATC CTTCTTAAAT
101	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG CGGTTCTGTC C K L	$\begin{array}{c cccc} TGAAGACAATC \\ ACTTCTTTAG \\ L & C & Q \\ \hline CTCTGTCAGG \\ GAGACAGTCC \\ E & E & K \\ \hline GGAAGACAAAA \\ CCTTCTTTTT \\ A & G & K & G \\ \hline CAGGCAAAGG \\ GTCCGTTCC \\ S & G & Q \\ \hline \end{array}$	$\begin{array}{c cccc} CCTGTTACTC\\ GGACATTACTC\\ E & E & R & N\\ AAGAGAGATACTCTCTTT\\ R & G & I\\ AGAGGTACTCCTCTCTTTAGGAGATACTCCTCCATAGGAGATACTCCATAGGAGATACTCCAGAGATACTCAGAGAATACTCAGAGATACTCAGAGATACTCAGAGATACTCAGAGATACTCAGAGAATACTCAGAGAATACTCAGAGATACTCAGAGAATACTCAGAGAATACTCAGAGAATACTCAGAGAATACTCAGAGAATACTCAGAGAATACTCAAATACTCAATACTCAGAATACTCAAATACTCAGAATACTCAAATACTCAATACTCAAATACTCAAATACTCAAATACTCAAATACT$	TTTTTCTTTC TTGGGACCAT AAAAAAGAAG AACCTGGTA A D E D D G TGCTGATGAG GACGATGCGG ACGACTACTC CTGCTACCCC CC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S S L L N H A S AGTCTGCTGA ATCATGCATC ATCATGCATC CTTCTTAAAT
101	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG CGGTTCTGTC C K L TTGTAAACTT	$\begin{array}{c cccc} TGAAGACATCTTTAG \\ ACTTCTTTAG \\ L & C & Q \\ \hline L & C & Q \\ \hline CTCTGTCTCC \\ E & E & K \\ \hline GGAAGACAAAA \\ \hline CCTTCTTTT \\ A & G & K & G \\ \hline CAGGCCGTTTCC \\ S & G & Q \\ \hline TCTGGACAAAA \\ \hline \\ \hline \\ TCTGGACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA$	$\begin{array}{c c} CCTGTTACTC\\ GGACATA \\ E & E & R & N\\ AAGAGATA \\ TCTCTCTTTT\\ R & G & I\\ AGAGATA \\ ACGCGATA \\ ACGCGATA \\ ACGCGATA \\ C & *\\ GTABATA \\ ACGCGATA \\ ACG$	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S L L N H A S AGTCTGCTGA ATCATGCATC TCAGACGACT TAGTACGTAG
101	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG CGGTTCTGTC C K L TTGTAAACTT AACATTTGAA	TGAAGAAATC ACTTCTTTAG L C Q CTCTGTCAGG GAGACAAAAA CCTTCTTTTT A G K G CAGGCAAAGG GTCCGTTCC S G Q TCTGGACAATA	$\begin{array}{c cccc} & & & & & & & \\ & & & & & & & \\ E & & E & & R & & N \\ & & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & \\ & & & & $	TTTTTCTTTC TTGGGACCAT AAAAAAGAAGA AACCCTGGTA A D E D D G TGCTGATACCCC ACGACTACTC CTGCTACCCC CC L N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S ACCTATGCGA ATCATGCATC TCAGGACGACT TAGTACGTAG TCAGACGACT TAGTACGTAG GAATTGGAAG TCATTTGATG
101 151 201	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG CGGTTCTGTC C K L TTGTAAACTT AACATTTGAA CAGAATATCA	TGAAGACUTTTAG L C Q CTCTGTCAGG GAGACATCC E E K GGAAGAAAAA CCTTCTTTTT A G K G CAGGCAAAGG GTCCGTTCC S G Q TCTGGACAAT AGACCTGTAA	$\begin{array}{c cccc} & & & & & & & \\ & & & & & & & \\ E & & E & & R & & N \\ & & & & & & & \\ & & & & & & \\ & & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & $	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S L L N H A S AGTCTGCTGA ATCATGCATC TCAGACGACT TAGTACGTAG GAATTGGAAG TCATTTGATG GAATTGGAAG TCATTTGATG CTTAACCTTC AGTAAACTAC
101 151 201	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG CGGTTCTGTC C K L TTGTAAACTT AACATTTGAA CAGAATATCA	TGAAGACUTTTAG L C Q CTCTGTCAGG GAGACATCC E E K GGAAGAAAAA CCTTCTTTTT A G K G CAGGCAAAGG GTCCGTTCC S G Q TCTGGACAAT AGACCTGTAA	$\begin{array}{c cccc} & & & & & & & \\ & & & & & & & \\ E & & E & & R & & N \\ & & & & & & & \\ & & & & & & \\ & & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & $	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S L L N H A S AGTCTGCTGA ATCATGCATC TCAGACGACT TAGTACGTAG GAATTGGAAG TCATTTGATG CTTAACCTTC AGTAAACTAC CTGATAAAAAAAAAAAAAAAAAAAAAAA
51 101 151 201 251	ATGTTCACCT TACAAGTGGA S L S CTCCTTATCT GAGGAATAGA E M T E AAATGACAGA TTTACTGTCT A K T GCCAAGACAG CGGTTCTGTC C K L TTGTAAACTT AACATTTGAA CAGAATATCA GTCTTATAGT	TGAAGACUTTTAG L C Q CTCTGTCAGG GAGACATCC E E K GGAAGAAAAA CCTTCTTTTT A G K G CAGGCAAAGG GTCCGTTCC S G Q TCTGGACAAT AGACCTGTAA	$\begin{array}{c cccc} & & & & & & & \\ & & & & & & & \\ E & & E & & R & & N \\ & & & & & & & \\ & & & & & & \\ & & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & $	TTTTTCTTTC TTGGGACCAT AAAAAGAAAG AACCCTGGTA A D E D D G TGCTGATGAG GACGATGGGG ACGACTACTC CTGCTACCCC L D T L K N L TGGATACGCT GAAGAATTTA ACCTATGCGA CTTCTTAAAT S L L N H A S AGTCTGCTGA ATCATGCATC TCAGACGACT TAGTACGTAG GAATTGGAAG TCATTTGATG CTTAACCTTC AGTAAACTAC CTGATAAAAAAAAAAAAAAAAAAAAAAA

M F T L K K S L L L F F F L G T I

Fig 2. (1) FLPVLAGIAAKVVPALFCKITKKC Brevinin-1 (1) FLPLLAGLAANFLPKIFCKITRKC Brevinin-1E (1) FLPAIFRMAAKVVPTIICSITKKC Brevinin-1Ea Brevinin-1Eb (1) VIPFVASVAAEMQ-HVYCAASRKC Brevinin-1Ecb (1) FLPLLAGLAANFFPKIFCKITRKC (1) VIPFVASVAAEMMQHVYCAASRRO Brevinin-1Ra Formatted: Font: (Default) Courier New, 10 pt, Bold Formatted: Font: (Default) Courier New, 10 pt, Bold, Font Brevinin-2 -GLLDSLKGFAATAGKGVLQSLLSTASCKLAKTC (1) -GIMDTLKNLAKTAGKGALQSLLNKASCKLSGQC Brevinin-2E -GILDTLKNLAISAAKGAAQGLVNKASCKLSGQC Brevinin-2Ea -GILDTLKNLAKTAGKGALQGLVKMASCKLSGQC Brevinin-2Eb (1) GILLDKLKNFAKTAGKGVLQSLLNTASCKLSGQC Brevinin-2Ec (1) -GILDSLKNLAKNAG----QILLNKASCKLSGQC Brevinin-2Ed (1) -GIMDTLKNLAKTAGKGALQSLVKMASCKLSGQC Brevinin-2Ef (1) -GIMDTLKNLAKTAGKGALQSLLNHASCKLSGQC Brevinin-2Eg (1) -GIMDTLKNLAKTAGKGALQSLLNHASCKLSKQC (1) -GILDTLKNLAKTAGKGILKSLVNTASCKLSGQC Brevinin-2Eh Brevinin-2Ei Brevinin-2Ej (1) GIFLDKLKNFAK----GVAQSLLNKASCKLSGQC Brevinin-2Tbe (1) -GILDTLKNLAKTAGKGALQSLLNHASCKLSGQC Formatted: Font: (Default) Courier New, 10 pt, Bold Formatted: Font: (Default) Courier New, 10 pt, Bold, Font (b) Esculentin-1 (1) GIFSKFGRKKIKNLLISGLKNVGKEVGMD--VVRTGIDIAGCKIKGEC Esculentin-1a GIFSKLAGKKIKNLLISGLKNVGKEVGMD--VVRTGIDIAGCKIKGEC Esculentin-1b (1) GIFSKLAGKKLKNLLISGLKNVGKEVGMETDVVRTGIDIAGCKIKGEC Esculentin-1c (1) GIFSKLAGKKIKNLLISGLKNIGKEVGMD--VVRTGIDIAGCKIKGE Formatted: Font: (Default) Courier New, 10 pt, Bold Formatted: Font: (Default) Courier New, 10 pt, Bold (1) GILSLVKGVAKLAGKGLAKEGGKFGLELIACKIAKQC Esculentin-2a (1) GIFSLVKGAAKLAGKGLAKEGGKFGLELIACKIAKQC Esculentin-2b (1) GIFSLVKGAAKLLGKGLAKEGGKFGLELMACKIAKQC Esculentin-2c Formatted: Font: (Default) Courier New, 10 pt, Bold, Font Formatted: Font: (Default) Courier New, 10 pt. Bold

Fig 3.



<u>#1</u>	<u>b(1+)</u>	<u>b(2+)</u>	Seq.	<u>y(1+)</u>	<u>y(2+)</u>	<u>#2</u>
1	115.05021	58.02874	<u>N</u>	_	_	<u>12</u>
2	228.13428	114.57078	<u>L</u>	1273.65109	637.32918	<u>11</u>
<u>3</u>	<u>285.15575</u>	143.08151	<u>G</u>	1160.56702	<u>580.78715</u>	<u>10</u>
4	413.25072	207.12900	<u>K</u>	1103.54555	552.27641	9
<u>5</u>	541.30930	271.15829	Q	975.45058	488.22893	<u>8</u>
<u>6</u>	727.38862	364.19795	W	847.39200	424.19964	<u>7</u>
<u>7</u>	798.42574	<u>399.71651</u>	<u>A</u>	661.31268	331.15998	<u>6</u>
<u>8</u>	897.49416	449.25072	<u>V</u>	<u>590.27556</u>	295.64142	<u>5</u>
<u>9</u>	<u>954.51563</u>	477.76145	<u>G</u>	491.20714	246.10721	<u>4</u>
<u>10</u>	1091.57454	546.29091	<u>H</u>	434.18567	217.59647	<u>3</u>
<u>11</u>	1238.64296	619.82512	<u>F</u>	297.12676	149.06702	2
<u>12</u>	_	_	M	150.05834	75.53281	<u>1</u>

Formatted: Font: Calibri, 11 pt